HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rennard, S. I. Articles by Farmer, S. G. Search for Related Content PubMed PubMed Citation Articles by Rennard, S. I. Articles by Farmer, S. G.

Exacerbations and Progression of Disease in Asthma and Chronic Obstructive Pulmonary Disease

University of Nebraska Medical Center, Omaha, Nebraska; and AstraZeneca Pharmaceuticals, Wilmington, Delaware

Correspondence and requests for reprints should be addressed to Stephen I. Rennard, M.D., Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, 985885 Nebraska Medical Center, Omaha, NE 68198–5885. E-mail: srennard{at}unmc.edu

Exacerbations, characterized by an increase in patients' symptoms above baseline, are characteristic of both chronic obstructive pulmonary disease (COPD) and asthma. Prevention of exacerbations and their expedient treatment are major goals for reducing the morbidity and cost of both conditions. Exacerbations, however, may also adversely affect the natural history of these disorders, perhaps by contributing to increased rates of lung function decline, systemic effects, and premature mortality. Although the available information is limited, the course of COPD is affected adversely by exacerbations in multiple ways. First, exacerbations likely lead to structural alterations in the lung and to permanently worsened airflow. Second, health status is adversely affected by exacerbations, and although the mechanisms are unclear, the effects are long lasting and may be irreversible. Less is known in asthma about the effect of exacerbations on natural history, but many of the same pathogenetic processes involved in COPD exacerbations likely play a role in some subjects with asthma as well. Future studies of how exacerbation affects the "natural history" of asthma and COPD will require a better understanding of the heterogeneity of exacerbations but promises to identify new therapeutic strategies to treat these disorders.

Key Words: chronic obstructive pulmonary disease • asthma • exacerbation • disease progression • emphysema

This article has been cited by other articles:

				M. R. Sears Lung function decline in asthma Eur. Respir. J., September 1, 2007; 30(3): 411 - 413. [Full Text] [PDF]

				E. L. Martin, T. A. Sheikh, K. J. Leco, J. F. Lewis, and R. A. W. Veldhuizen Contribution of alveolar macrophages to the response of the TIMP-3 null lung during a septic insult Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L779 - L789. [Abstract] [Full Text] [PDF]

				P. M. A. Calverley Exercise and dyspnoea in COPD Eur. Respir. Rev., December 1, 2006; 15(100): 72 - 79. [Abstract] [Full Text] [PDF]

				N W Johnston and M R Sears Asthma exacerbations {middle dot} 1: Epidemiology. Thorax, August 1, 2006; 61(8): 722 - 728. [Abstract] [Full Text] [PDF]

				S. I. Rennard and N. Voelkel Introduction Proceedings of the ATS, April 1, 2005; 2(1): 7 - 7. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]